Grading the Lifecycle Playbook: What Keytruda, Stelara, and Eliquis Reveal About Patent-Cliff Strategy
Johnson & Johnson’s Stelara sales fell 59.7% year over year in the first quarter of 2026, to $656 million, after
Evergreening Fails When a Judge Reads Your Own Marketing Materials
Forest Laboratories and Actavis projected that only 30 percent of Namenda IR users would move to Namenda XR voluntarily before
Evergreening Fails When a Judge Reads Your Own Marketing Materials Read Post »
Pay-for-Delay After Actavis: The Side Deal Is the Risk
In fiscal year 2021, drug companies filed 199 final patent settlements with the FTC. Twenty-two of them came with a
Pay-for-Delay After Actavis: The Side Deal Is the Risk Read Post »
Why Filing More Continuations Doesn’t Extend Your Moat: It Just Extends Your Legal Bill
AbbVie’s U.S. Humira revenue fell from $18,619 million in 2022 to $12,160 million in 2023. That is a drop of
Why Filing More Continuations Doesn’t Extend Your Moat: It Just Extends Your Legal Bill Read Post »
The Pediatric Exclusivity Extension You Celebrated Gave Your Board a False Sense of Runway
As of July 16, 2026, FDA lists 354 pediatric exclusivity determinations. They cover 321 approved active moieties. [1] Each determination
The Patent Expiration Date on the Label Isn’t the Date That Matters — Here’s the One Your Model Is Missing
Three Orange Book patent dates fall within 16 days of each other this November. Entresto’s first listed patent expires on
The Drug Patent Cliff Is a Modeling Error: Why One Generic-Entry Date Breaks Your Pharma DCF
Bristol Myers Squibb reported $12,821 million in worldwide Revlimid revenue for 2021 [1]. It reported $2,951 million for 2025 [3].
The Analyst Note That Said “Patent Cliff Priced In” Never Checked Whether the Patent Was Even Valid
Novartis reported Entresto sales of $1,253 million in the fourth quarter of 2025. That figure was 43% below the $2,180
Stop Valuing Biosimilar Risk Like Small-Molecule Generic Risk: The Entry Curves Aren’t the Same Shape
AbbVie’s U.S. Humira revenue fell from $7,142 million in 2024 to $3,062 million in 2025, a 57.1% drop, two years
